NKGen Biotech (NKGN) shares rose by more than 24% in recent Wednesday trading after the company said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.
The designation follows positive phase 1 trial results, which showed early signs of clinical benefit for patients treated with troculeucel, the company said.
NKGen is currently enrolling patients its phase 2a trial for moderate Alzheimer's disease patients and plans to release updated clinical data by the end 2025.
Price: 0.47, Change: +0.09, Percent Change: +24.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.